Rep. Lisa C. McClain Sells Off Shares of Sanofi (NASDAQ:SNY)

Key Points

• Representative Lisa C. McClain sold shares of Sanofi (NASDAQ:SNY) for between $1,001 and $15,000 on July 22nd as part of her financial disclosures.
• Sanofi reported a net loss in EPS this quarter, earning $0.90 per share, which was below the consensus estimate of $0.96.
• Institutional investors have increasingly shown interest in Sanofi, with a notable increase in stakes from companies like Ameritas Advisory Services and Bessemer Group.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Sanofi NASDAQ: SNY. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Sanofi stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Apple NASDAQ: AAPL on 7/22/2025.

Sanofi Stock Performance

NASDAQ:SNY traded up $0.35 during midday trading on Tuesday, reaching $50.19. 1,734,551 shares of the company traded hands, compared to its average volume of 2,580,671. Sanofi has a twelve month low of $44.73 and a twelve month high of $60.12. The firm has a market capitalization of $123.24 billion, a price-to-earnings ratio of 12.06, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The company has a fifty day moving average price of $48.57 and a 200 day moving average price of $51.78.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the prior year, the firm earned $1.73 EPS. The company's revenue for the quarter was down 7.0% compared to the same quarter last year. On average, analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Sanofi

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. B. Riley Wealth Advisors Inc. acquired a new stake in Sanofi during the 2nd quarter valued at $715,000. Asset Dedication LLC increased its stake in shares of Sanofi by 46.8% in the 2nd quarter. Asset Dedication LLC now owns 1,815 shares of the company's stock valued at $88,000 after buying an additional 579 shares during the period. Geneos Wealth Management Inc. increased its stake in shares of Sanofi by 33.1% in the 2nd quarter. Geneos Wealth Management Inc. now owns 15,938 shares of the company's stock valued at $770,000 after buying an additional 3,960 shares during the period. Rexford Capital Inc. acquired a new stake in shares of Sanofi in the 2nd quarter valued at $493,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Sanofi by 243.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,450 shares of the company's stock valued at $215,000 after buying an additional 3,154 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SNY. JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, Sanofi presently has an average rating of "Buy" and a consensus target price of $62.00.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.